Advancing BMB-101, a highly selective 5-HT2C receptor agonist, through Phase 3 global registrational trials for Developmental and Epileptic Encephalopathies (DEEs) and Absence Epilepsy, as well as progressing the Phase 2a NOVA trial for Prader-Willi Syndrome.

Expected impact: Establishment of a best-in-class, highly selective anti-seizure and neurodevelopmental therapy, paving the way for regulatory approvals and commercialization.

Expanding the neuropsychiatric and neurological pipeline by nominating and preparing new chemical entities (NCEs) for clinical entry. This includes advancing BMB-105 as a dedicated candidate for Prader-Willi Syndrome and progressing selective 5-HT2A agonists (BMB-201 and BMB-202) through IND-enabling preclinical studies for depression and other CNS disorders.

Expected impact: Diversification of the clinical portfolio beyond epilepsy into broader neuropsychiatry and rare genetic disorders, creating multiple avenues for value creation.

Actively seeking strategic collaborations, licensing agreements, or co-development partnerships with major pharmaceutical companies to monetize its patented portfolio of selective serotonin agonists.

Expected impact: Securing non-dilutive funding through upfront payments, clinical/regulatory milestones, and future royalties, while leveraging partner capabilities for global commercialization.